Neuren Pharmaceuticals Limited (AU:NEU)
ASX:NEU
NEU Stock Chart & Stats
AU$12.03
-AU$0.38(-3.05%)
At close: 4:00 PM EST
AU$12.03
-AU$0.38(-3.05%)
Day’s Range― - ―
52-Week RangeAU$8.62 - AU$22.99
Previous CloseN/A
Volume294.48K
Average Volume (3M)305.98K
Market Cap
AU$1.52B
Enterprise ValueAU$1.66B
Total Cash (Recent Filing)AU$296.12M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)78.4
Beta2.31
Next Earnings
Aug 25, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.12
Shares Outstanding126,639,530
10 Day Avg. Volume278,541
30 Day Avg. Volume305,983
Financial Highlights & Ratios
PEG Ratio-1.00
Price to Book (P/B)7.05
Price to Sales (P/S)36.92
P/FCF Ratio19.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$25.54Price Target Upside112.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.15
Revenue Forecast (FY)AU$83.75M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA zero-debt balance sheet materially reduces financial risk and preserves strategic optionality. It lowers fixed obligations and interest exposure, enabling Neuren to fund R&D, pursue licensing or milestone-driven deals, and withstand cyclical revenue swings without immediate refinancing pressure.
Sustained High MarginsConsistently high gross and operating margins indicate structural unit economics that can support durable profitability. Strong margins improve cash retention per revenue dollar, helping fund clinical programs and partner negotiations even if top-line growth is uneven over a multi‑quarter horizon.
Partnered Commercial Revenue StreamA partnership with an established commercial partner creates a scalable revenue channel without large in‑house commercialization cost. Royalties and milestones can provide recurring or event-driven cash inflows that support development of NNZ‑2591 and reduce single‑party commercialization risk for Neuren.
Bears Say
Revenue Volatility And DeclinePronounced top-line swings reduce visibility into sustainable earnings and complicate multi‑period planning. Sharp revenue declines can erode operating leverage, pressure margins over time, and force dependence on one-off partner payments or financing to fund pipeline activities if not stabilized.
Inconsistent Cash Flow ConversionIrregular conversion of profits to cash creates funding uncertainty for clinical programs and overhead. Years with negative operating/free cash flow despite accounting profits increase the likelihood of needing external funding or milestone monetization, weakening predictability of reinvestment capacity.
Revenue Concentration On PartnershipsDependence on partner royalties and milestone payments concentrates revenue risk: timing and magnitude are contingent on partner commercial performance and contract triggers. Limited internal commercialization scale (employees: 8) magnifies reliance on partners for sustained revenue generation.
Neuren Pharmaceuticals Limited News
NEU FAQ
What was Neuren Pharmaceuticals Limited’s price range in the past 12 months?
Neuren Pharmaceuticals Limited lowest share price was AU$8.62 and its highest was AU$22.98 in the past 12 months.
What is Neuren Pharmaceuticals Limited’s market cap?
Neuren Pharmaceuticals Limited’s market cap is AU$1.52B.
When is Neuren Pharmaceuticals Limited’s upcoming earnings report date?
Neuren Pharmaceuticals Limited’s upcoming earnings report date is Aug 25, 2026 which is in 138 days.
How were Neuren Pharmaceuticals Limited’s earnings last quarter?
Neuren Pharmaceuticals Limited released its earnings results on Feb 26, 2026. The company reported AU$0.118 earnings per share for the quarter, beating the consensus estimate of AU$0.014 by AU$0.104.
Is Neuren Pharmaceuticals Limited overvalued?
According to Wall Street analysts Neuren Pharmaceuticals Limited’s price is currently Undervalued.
Does Neuren Pharmaceuticals Limited pay dividends?
Neuren Pharmaceuticals Limited does not currently pay dividends.
What is Neuren Pharmaceuticals Limited’s EPS estimate?
Neuren Pharmaceuticals Limited’s EPS estimate is 0.07.
How many shares outstanding does Neuren Pharmaceuticals Limited have?
Neuren Pharmaceuticals Limited has 126,639,530 shares outstanding.
What happened to Neuren Pharmaceuticals Limited’s price movement after its last earnings report?
Neuren Pharmaceuticals Limited reported an EPS of AU$0.118 in its last earnings report, beating expectations of AU$0.014. Following the earnings report the stock price went down -2.902%.
Which hedge fund is a major shareholder of Neuren Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in AU:NEU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neuren Pharmaceuticals Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$25.54 (112.28% Upside)
AU$25.54 (112.28% Upside)
Blogger Sentiment
Bullish
AU:NEU Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $104.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
63.76%
12-Months-Change
Fundamentals
Return on Equity
9.20%
Trailing 12-Months
Asset Growth
-9.87%
Trailing 12-Months
Company Description
Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.
NEU Stock 12 Month Forecast
Average Price Target
AU$25.54
▲(112.28% Upside)
Technical Analysis
Clinuvel Pharmaceuticals
―
Mesoblast Limited
―
Orthocell Ltd
―
Alterity Therapeutics
―
Immutep Ltd
―
Options Prices
Currently, No data available
---